1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Recommended Citation
Thapa B, Henderson N, Tagawa ST, Hwang C, Sokolova AO, Bilen MA, Coelho Barata PM, Nguyen CB, Tripathi A, Ayanambakkam A, Graham LS, Zakharia Y, Koshkin VS, Heath E, Dorff TB, Armstrong AJ, McKay RR, Alva AS, Schweizer M, Kilari D. 1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC). Ann Oncol 2024; 35:S991.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
Ann Oncol
Abstract
Background: Compound alterations in TP53, RB1, and/or PTEN have been correlated with poor outcomes in pts with mPC; however, there is limited data regarding whether PTEN alterations(alt) by next generation sequencing (NGS) are prognostic in isolation. PTEN -null de novo mPC is currently being investigated in CAPItello-281 and may represent a clinically actionable subtype. As such, we sought to characterize outcomes of this genomically defined subgroup. Methods: PROMISE is a multi-institutional database including mPC pts (N=2027) with NGS. Using PROMISE, we analyzed outcomes based on PTEN status in de novo mPC pts. Results: Among 1036 pts with de novo mPC, 212 (20%) had PTEN alt by NGS. Median age at diagnosis was 64 yrs, 21% were Black, 53% had high volume (HV) disease. Compared to the PTEN-wildtype (wt) group, PTEN-altered mPC had higher co-occurrence of TP53 and/or RB1 mutations (57% vs 37%); lower median PSA (38 vs 63 ng/ml); and more visceral disease (18 vs 11%). Groups were otherwise similar. The table shows univariate (UVA) outcomes based on PTEN status. Outcomes were similar in men with high volume disease on UVA. On multivariable analysis controlling for clinical prognostic features and TP53/RB1 alterations, PTEN status remained independently associated with overall survival (OS) [HR 1.27, 95% CI (0.99, 1.63) p=0.05]. [Formula presented] Conclusions: PTEN status correlated with poor outcomes in de novo mPC independent of other clinical and genomic factors. Legal entity responsible for the study: The authors. Funding: AstraZeneca. Disclosure: D. Kilari: Financial Interests, Personal, Invited Speaker: Janssen, Pfizer, Aveo oncology, Seagen, MJH - Life Sciences, Binaytara Foundation; Financial Interests, Personal, Advisory Board: Exelixis, Eisai; Financial Interests, Institutional, Coordinating PI: Exelixis, Genentech. All other authors have declared no conflicts of interest.
Volume
35
First Page
S991
